- Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa studyMarta Osorio
Clinical Trials Unit, National Institute of Oncology and Radiobiology, Havana City, Cuba
Cancer Biol Ther 7:488-95. 2008..The prognostic value of autoimmunity and the possibilities of dissociating anti-tumor immunity from autoimmunity deserve further research...
- Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccineAdriana Carr
Center of Molecular Immunology and National Institute of Oncology and Radiobiology, Havana, Cuba
J Clin Oncol 21:1015-21. 2003..A phase I clinical trial was performed to determine safety and immunogenicity of this vaccine...